VivoSeq
Psychiatry

Nicotine Withdrawal

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Nicotine Withdrawal is an early-stage landscape with 0 programs across 1 company. The most active players are Promentis Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Promentis Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Recruiting1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Effects of Cannabidiol on Stress and Nicotine Withdrawal
Recruiting·JJohns Hopkins University·Phase 1·NCT07001930·90 enrolled
Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
Not yet recruiting·—·N/A·NCT07466875·60 enrolled
Neural Substrates in Nicotine Withdrawal
Completed·UUniversity of Pennsylvania·Phase 2·NCT01001520·218 enrolled
Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1
Completed·National Institute on Drug Abuse (NIDA)·Phase 2·NCT00218140
Nicotine Withdrawal Symptoms and Smoking Relapse
Completed·National Institute on Drug Abuse (NIDA)·N/A·NCT01511614·112 enrolled
Effects of Metformin During Nicotine Withdrawal
Completed·UUniversity of Pennsylvania·Phase 2·NCT03593538·80 enrolled
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Completed·PPromentis Pharmaceuticals, Inc.·Phase 2·NCT03887429·34 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)